
Researchers in Tianjin, China, have employed all ion unfolding–ion mobility–mass spectrometry (AIU–IM–MS) to enhance the differentiation of therapeutic polyclonal antibodies, offering insights into improvements in conformational stability and advantages in cost-effectiveness.






























